KiraGen Bio engineers healthy-donor CAR-T therapies for solid tumors, led by the preclinical program KGEN-001 for recurrent glioblastoma, which uses dual targeting and six coordinated base edits to pursue programmable durability. The company connects machine-learning predictions with experiments through KiraLOGIC to prioritize combinations of protective gene edits. In recurrent glioblastoma, existing CAR-T approaches can shrink tumors but tumor control often does not last.
KiraGen Bio builds CAR-T cells to ignore multiple tumor signals rather than overpower them, using combinations of coordinated gene edits designed to resist multiple tumor shutdown signals. Patient evidence guides which protections the company pursues, and multiplex editing lets it test those protections together. Its team includes members who have advanced multiplex base-edited CAR-T cells from research into clinical development.